Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid
S. Morteza Seyed Jafari, Laurence Feldmeyer, Simon Bossart, Dagmar Simon, Christoph Schlapbach, Luca Borradori
Abstract
Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.
Topics & Concepts
DupilumabOmalizumabMedicineBullous pemphigoidDermatologyMonoclonalMonoclonal antibodyBenralizumabRefractory (planetary science)PemphigoidImmunoglobulin EImmunologyAtopic dermatitisAntibodyAsthmaMepolizumabEosinophilAstrobiologyPhysicsAutoimmune Bullous Skin DiseasesCoagulation, Bradykinin, Polyphosphates, and AngioedemaUrticaria and Related Conditions